1.Clinic Study on the Adefovir Dipivoxil Treat Patients with HBeAg(+) Hepatitis B Resistant to Lamivudine 2.Preliminary Study on the Effect of Severe Hepatitis Plasma on Umbilical Cord Blood Mesenchymal Stem Cells in Vitro
Results: The positive rate of HCV Ags expression was 45% (9/20) in severe viral hepatitis, 60% (6/10) in chronic severe hepatitis, 42.9% (3/7) in subacute severe hepatitis and 0%(0/3) in acute severe hepatitis.
Only two of the 13 superinfected patients showed a severe hepatitis, but a high percentage (78%) of them developed chronic hepatitis one year after HDV infection.
A clinically more severe hepatitis was seen significantly more often among the HDV co-infected patients than among the solely HBV infected.
The HDAg detection rate in chronic liver diseases and severe hepatitis was higher than in other liver diseases.
Among 276 patients, there were 78 cases of HBV asymptomatic carriers, 110 cases of chronic hepatitis B (CHB), 62 cases of severe hepatitis (SH) or liver cirrhosis (LC) and 26 cases of hepatocellular carcinoma (HCC).
Without any clinical or laboratory signs of severe hepatitis, the patient developed a histologically proven complete liver cirrhosis within 8 months after reinfection of the graft.
Study on FAS/FAS-L expression in liver tissue and hepatocyte apoptosis in patients with hepatitis gravis
It was found that in the 20 patients with clinical hepatitis gravis, Fas in hepatocytes showed strong expression and Fas-L also showed intensive expression in infiltrating lymphocytes and scattering hepatocytes.
It was suggested that the overexpression of Fas/Fas-L could cause the death of hepatocytes and thus the occurrence of hepatitis gravis.
The apoptosis caused by Fas might be one of the important pathogeneses of hepatitis gravis.
Among the detected samples, apoptosis and necrosis coexisted, indicating that both two types of cellular death were closely associated with the pathogenesis of hepatitis gravis.